Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing

Author:

UK-based biotech company Prozomix and bioworks company Ginkgo Bioworks have announced a new partnership to develop next-generation enzyme plates for active pharmaceutical ingredient (API) manufacturing. The collaboration aims to leverage Ginkgo’s Enzyme Services and industry-leading AI/ML models with Prozomix’s enzyme libraries and manufacturing expertise.

As part of the agreement, Prozomix will join Ginkgo’s Technology Network, a ecosystem of technology partners focused on driving innovation in customer R&D programs. This enables Ginkgo customers to access Prozomix’s scalable contract manufacturing services, including enzyme samples from mg to kg scale.

The adoption of biocatalysts in commercial API manufacturing has been driven by the need for improved supply chain sustainability and reduced costs. Prozomix and Ginkgo’s partnership aims to develop a new generation of biocatalysts using enzyme sequence and activity data from previous libraries. Ginkgo will build AI models based on these data to discover novel functional enzyme sequences. Prozomix will then manufacture enzyme plates using these next-gen libraries, aiming to offer diversity and performance that traditional plates lack.

The partners envision these next-gen enzyme plates to unlock new biocatalytic opportunities for pharma process chemistry groups. The plates will be freely available, with the condition that screening data is shared with Ginkgo to further refine their AI/ML models.

Simon J. Charnock, CEO of Prozomix, believes that the partnership with Ginkgo will keep Prozomix at the forefront of best-in-class biocatalyst provision throughout the AI revolution. Cindy Chang, Senior Director of Business Development at Ginkgo Bioworks, sees the collaboration as an opportunity to benefit API manufacturing through enzyme engineering and AI/ML models.

Overall, the partnership between Prozomix and Ginkgo Bioworks aims to advance enzyme development for sustainable API manufacturing and offers potential benefits in cost reduction and supply chain sustainability for the pharmaceutical industry.

The partnership between Prozomix and Ginkgo Bioworks is focused on developing next-generation enzyme plates for active pharmaceutical ingredient (API) manufacturing. This collaboration combines Ginkgo’s Enzyme Services and advanced AI/ML models with Prozomix’s enzyme libraries and expertise in manufacturing.

The adoption of biocatalysts in commercial API manufacturing has become increasingly important due to the demand for improved supply chain sustainability and reduced costs in the industry. Prozomix and Ginkgo aim to develop a new generation of biocatalysts by utilizing enzyme sequence and activity data from previous libraries. Ginkgo will utilize this data to build AI models that can identify novel functional enzyme sequences.

The ultimate goal of the partnership is to manufacture enzyme plates using these next-gen libraries, providing the pharmaceutical industry with increased diversity and performance compared to traditional plates. By unlocking new biocatalytic opportunities for pharma process chemistry groups, these enzyme plates have the potential to benefit API manufacturing.

Under the partnership, the next-gen enzyme plates will be made freely available with the condition that screening data is shared with Ginkgo. This data will be used to further refine their AI/ML models, contributing to continuous improvement in enzyme development.

Prozomix’s CEO, Simon J. Charnock, believes that the collaboration with Ginkgo will position Prozomix as a leader in biocatalyst provision during the AI revolution. Cindy Chang, the Senior Director of Business Development at Ginkgo Bioworks, sees the partnership as an opportunity to advance API manufacturing through enzyme engineering and AI/ML models.

In summary, this partnership between Prozomix and Ginkgo Bioworks aims to advance enzyme development for sustainable API manufacturing. By leveraging AI/ML models and incorporating enzyme libraries, the collaboration offers potential benefits in cost reduction and supply chain sustainability for the pharmaceutical industry.

For more information about Prozomix, visit their website.
To learn more about Ginkgo Bioworks, visit their website.